Opinion|Videos|September 27, 2024

Frontline Treatment and Sequencing Therapy

Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.

Video content above is prompted by the following:

  • What does your institution use for frontline treatment and how do you sequence therapy for patients who are transplant-eligible?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME